About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 958 record(s)
Req # A-2021-000663
Adverse Drug Reaction (ADR) for HYOSCINE BUTYLBROMIDE. Report number: E2B_03293753.Organization: Health Canada
September 2023
Req # A-2022-001661
Adverse Drug Reaction (ADR). Report number: E2B_05716216.Organization: Health Canada
September 2023
Req # A-2023-000352
Adverse Drug Reaction (ADR) for LANREOTIDE. Report number: E2B_05322380.Organization: Health Canada
September 2023
Req # A-2023-000381
Adverse Drug Reactions (ADRs) for ZOSTAVAX II. Report numbers: E2B_03009425, E2B_01335934, E2B_02096585, E2B_01892634, E2B_02393844, E2B_02387551, E2B_02826826, E2B_02867073, E2B_02455143, E2B_03044908.Organization: Health Canada
September 2023
Req # A-2023-000416
Adverse Drug Reaction (ADR). Report number: 000630138.Organization: Health Canada
September 2023
Req # A-2023-000468
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-103496-815, Investing in Canada Plan.Organization: Health Canada
September 2023
Req # A-2023-000529
Adverse Drug Reaction (ADR). Report number: E2B_02891245.Organization: Health Canada
September 2023
Req # A-2023-000548
Adverse Drug Reaction (ADR). Report number: E2B_06076856.Organization: Health Canada
September 2023
Req # A-2023-00083
Copies of all records including policies, guidelines and protocols with respect to the LP01 to LP02 Development Program.Organization: Department of Justice Canada
August 2023
Req # A-2023-00113
January 2023 Briefing Note: 2022-012386 Meeting with David Van Der Woerd, President, Hamilton Law Association (For Information).Organization: Department of Justice Canada
August 2023